Pioneering Pre-Clinical and Phase I Solutions: Where AI-Driven R&D Meets Expert Execution For Inclusive Health
Rubix LS merges cutting-edge research and development with comprehensive CRO services, accelerating the journey from early discovery to clinical success.
OUR MISSION
A Seamless Fusion of R&D Innovation and CRO Precision
At Rubix LS, we stand at the forefront of biomedical advancement, embodying both a dynamic research and development powerhouse and a precision-driven contract research organization. Our dual expertise means not only do we innovate with AI-enhanced methodologies in drug discovery, but we also flawlessly execute pre-clinical and Phase I trials. This unique combination ensures that our partners benefit from groundbreaking research seamlessly translated into tangible clinical outcomes for underserved communities.
Empowering Innovation with Equity: Bridging Gaps in Healthcare
At Rubix LS, our commitment transcends the boundaries of traditional R&D and CRO execution. Positioned at the unique intersection of innovative research and precise clinical trial management, we're dedicated to not just advancing medical science but ensuring it reaches every corner of our society. By focusing our efforts on underserved and underrepresented patient groups, we aim to bring equity to the forefront of biomedical research. Our AI-driven methodologies are not only designed for efficiency and precision but are also tailored to address the unique challenges and needs of these communities, ensuring that our breakthroughs benefit all segments of society.
-
Inclusive Research Design: Incorporating diverse patient data to ensure our AI models and research methodologies are inclusive and representative.
-
Targeted Trial Recruitment: Striving for diversity in clinical trial recruitment to understand treatment efficacy across different populations better.
-
Community Engagement: Working closely with community leaders and patients to understand and address specific health disparities, ensuring our research has a meaningful and positive impact.
​
In-Licensing and Co-Development Expertise
Strategic Partnerships: By forging strong alliances with innovators and stakeholders, we transform potential therapies into accessible treatments.
​
Efficient Path to Market: AI helps us in navigating regulatory pathways and making informed decisions through the therapy development lifecycle, ensuring precision in our approaches.
Advancing Healthcare Equity: A Core Principle at Rubix LS
Healthcare equity is not just an ideal at Rubix LS; it's a practical, integrated aspect of our daily work. Our dual roles as an R&D innovator and a CRO executor are infused with a deep commitment to making healthcare accessible and equitable for underserved and underrepresented communities. By consciously directing our AI research and clinical trials to focus on these populations, we are working to close the gap in healthcare disparities, one innovation at a time.
​
We utilize AI coupled with our interests in specific therapeutic assets to run diverse clinical trials for underserved patients so they can take their data anywhere. At the same time, we enhance real-world evidence for highly prevalent conditions while increasing real world evidence for highly prevailing conditions that help expand commercialization potential.
Our R&D is designed to provide patients with the latest treatments and therapies. We work closely with healthcare providers and community organizations to ensure that targeted research and therapeutics are accessible to all who may benefit.
Our team of data analysts is dedicated to identifying trends and insights that can advance medical research. We use the latest data analysis tools and techniques to provide our clients with the most accurate and meaningful insights.
At Rubix LS, we stand as a trusted small business federal contractor, consistently delivering culturally competent research services tailored to the unique needs of the national community. When partnering with us, agencies secure a team that elevates research through cultural relevance and precision metrics, driving both effective and resonant outcomes.
Rubix LS In Numbers
100+
RESEARCH STUDIES
18+
CLINICAL TRIALS LAUNCHED
50+
MEDICAL EXPERTS
20+
PARTNERSHIPS
OUR PARTNERS
We Collaborate with Leading Medical Institutions
Rubix LS works with a range of partners to advance medical research and improve patient outcomes. Our partners include hospitals, universities, and other medical research organizations.
HOSPITALS
UNIVERSITIES
RESEARCH ORGANIZATIONS
PHARMA/BIOTECH/LIFE-SCIENCE